Use of Venetoclax , AML , Sohag , Egypt
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Status
- RECRUITING
- Phase
- PHASE3
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Newly-diagnosed Pediatric T-cell ALL Protocol
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Status
- RECRUITING
- Phase
- PHASE3
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
- Status
- SUSPENDED
- Phase
- PHASE1
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE2
Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE2
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
- Status
- RECRUITING
- Phase
- PHASE2
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
VHAG in Treating R/R T-ALL/LBL
- Status
- RECRUITING
- Phase
- PHASE2